Chronic liver disease is currently the 12th leading cause of death, accounting for 27,000 deaths and approximately $1.6 billion in economic costs per year in the U.S. Cholestatic liver diseases associated with poor bile flow comprise a significant proportion of these disorders. In fact, they comprise the majority of liver diseases in children and are the leading indication for childhood liver transplantation.
Most of these disorders progress to end-stage liver disease that is either fatal or requires liver transplantation, with a high personal and economic cost.
Despite substantial effort, there are no effective therapies to modulate the volume and composition of bile.
The long-term goal of our research is to develop new therapeutic strategies for the treatment of cholestatic liver diseases by modulating bile formation.